TO DEVELOP AND VALIDATE AN EFFECTIVE UPLC METHOD FOR THE DETERMINATION OFDARUNAVIR AND COBICISTAT IN BULK AND MULTI BRANDED FORMULATIONS

27^th International Congress on Pharmaceutical Biotechnology Research

June 23-24, 2025 Webinar

Revathi N, Upendra U, Rajkiran K

Department of Pharmaceutics, Sri Sivani College of Pharmacy, India

Scientific Tracks Abstracts: Pharm Regul Aff

Abstract :

A simple, rapid, precise, sensitive and reproducible reverse phase high performance liquid chromatography (UPLC)method has been developed for the quantitative analysis of Darunavir and Cobicistat in pharmaceutical dosage form.Chromatographic separation of Darunavir and Cobicistat was achieved on Waters Acquity UPLC system, by usingWaters X-bridge C8 100 x 3.0mm, 3.5μ column and the mobile phase containing 0.1% TFA & ACN in the ratio of40:60% v/v. The flow rate was 1.0 ml/min; detection was carried out by absorption at 257nm using a photodiodearray detector at ambient temperature. The number of theoretical plates and tailing factor for Darunavir andCobicistat were NLT 2000 and should not more than 2 respectively. % Relative standard deviation of peak areas of allmeasurements always less than 2.0. The proposed method was validated according to ICH guidelines. The methodwas found to be simple, economical, suitable, precise, accurate & robust method for quantitative analysis ofDarunavir and Cobicistat and study.UPLC Darunavir and CobicistatRevathi

Biography :

N.Revathi has her own experience in valuation and passion for ML and data. The research team built this model after many years ofexperience in research, evaluation, work in both hospitals and scientific laboratories. This approach meets all the requirements forprecise, specific, sensitive diagnostics..